drugset / Trial / NCT01900522

Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia

NCT01900522 ↗

Phase 1 Terminated 76 enrolled Takeda Intra-Cellular Therapies, Inc. · collab
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of this study is to characterize the safety and tolerability profile of ITI-214 when administered as multiple doses of oral solution at escalating dose levels.

Timeline

Start
2013-07
Primary completion
2014-09
Completion
2014-12

Outcome

Outcome not reported

Stopped (Business): “Business Decision; No Safety or Efficacy Concerns”

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenrispodun Small molecule — Oral

Indications